For the World Economic Forum, Alexandros Pantalis explains why phage therapy needs a different kind of regulation, and what France’s platform approach to veterinary phage medicines could mean for other countries.
Drug regulation was built around chemical medicines, each approved in one fixed formulation. Phage therapy doesn’t fit that mould: bacteria keep evolving, so the right phages for a given strain keep changing too.
Our CEO Alexandros Pantalis explains how France’s platform approach to veterinary phage medicines deals with that, and why it could serve as a model for other countries and, later, for human medicine.